LitCovid-sample-Enju  

PMC:7228307 / 60027-60294 JSONTXT 10 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T413 0-7 RB denotes Already
T414 7-8 -COMMA- denotes ,
T415 9-20 NN denotes engineering
T416 21-23 IN denotes of
T417 24-27 DT denotes the
T418 28-31 NN denotes IgG
T419 32-34 NN denotes Fc
T420 35-38 CC denotes and
T421 39-42 PRP-DOLLAR- denotes its
T422 43-49 NN denotes glycan
T423 50-53 VBZ denotes has
T424 54-60 VBN denotes proved
T425 61-62 DT denotes a
T426 63-69 JJ denotes potent
T427 70-73 CC denotes and
T428 74-83 JJ denotes effective
T429 84-92 NN denotes approach
T430 93-96 IN denotes for
T431 97-107 VBG denotes increasing
T432 108-111 DT denotes the
T433 112-120 JJ denotes clinical
T434 121-134 NN denotes effectiveness
T435 134-135 -COMMA- denotes ,
T436 136-146 JJ denotes functional
T437 147-158 NN denotes specificity
T438 159-162 CC denotes and
T439 163-169 NN denotes safety
T440 170-172 IN denotes of
T441 173-184 JJ denotes therapeutic
T442 185-189 NNS denotes mAbs
T443 190-193 CC denotes and
T444 194-196 VBZ denotes is
T445 197-199 DT denotes an
T446 200-208 VBG denotes emerging
T447 209-216 NN denotes pathway
T448 217-219 TO denotes to
T449 220-223 DT denotes the
T450 224-235 NN denotes development
T451 236-238 IN denotes of
T452 239-242 DT denotes the
T453 243-253 NN denotes “next‐gen”
T454 254-266 NNS denotes therapeutics
R423 T443 T413 arg1Of and,Already
R424 T443 T414 arg1Of and,","
R425 T415 T416 arg1Of engineering,of
R426 T420 T416 arg2Of and,of
R427 T419 T417 arg1Of Fc,the
R428 T419 T418 arg1Of Fc,IgG
R429 T419 T420 arg1Of Fc,and
R430 T422 T420 arg2Of glycan,and
R431 T422 T421 arg1Of glycan,its
R432 T415 T423 arg1Of engineering,has
R433 T424 T423 arg2Of proved,has
R434 T415 T424 arg1Of engineering,proved
R435 T435 T424 arg2Of ",",proved
R436 T429 T425 arg1Of approach,a
R437 T429 T426 arg1Of approach,potent
R438 T426 T427 arg1Of potent,and
R439 T428 T427 arg2Of effective,and
R440 T429 T428 arg1Of approach,effective
R441 T429 T430 arg1Of approach,for
R442 T431 T430 arg2Of increasing,for
R443 T434 T431 arg2Of effectiveness,increasing
R444 T434 T432 arg1Of effectiveness,the
R445 T434 T433 arg1Of effectiveness,clinical
R446 T429 T435 arg1Of approach,","
R447 T438 T435 arg2Of and,","
R448 T438 T436 arg1Of and,functional
R449 T437 T438 arg1Of specificity,and
R450 T439 T438 arg2Of safety,and
R451 T438 T440 arg1Of and,of
R452 T442 T440 arg2Of mAbs,of
R453 T442 T441 arg1Of mAbs,therapeutic
R454 T424 T443 arg1Of proved,and
R455 T444 T443 arg2Of is,and
R456 T415 T444 arg1Of engineering,is
R457 T447 T444 arg2Of pathway,is
R458 T447 T445 arg1Of pathway,an
R459 T447 T446 arg1Of pathway,emerging
R460 T447 T448 arg1Of pathway,to
R461 T450 T448 arg2Of development,to
R462 T450 T449 arg1Of development,the
R463 T450 T451 arg1Of development,of
R464 T454 T451 arg2Of therapeutics,of
R465 T454 T452 arg1Of therapeutics,the
R466 T454 T453 arg1Of therapeutics,“next‐gen”